智通财经网·2026-01-14 01:48Group 1 - China Biopharmaceutical (01177) has seen its stock price increase by over 5%, currently trading at HKD 7.24 with a transaction volume of HKD 303 million [1] - The company announced a full acquisition of Hejia, with the deal set to close on January 13, 2026, for a maximum base price of RMB 12 million, which may be adjusted and paid partially in cash and partially in shares [1] - Upon completion of the acquisition, Hejia will become a wholly-owned subsidiary of China Biopharmaceutical [1] Group 2 - Hejia is a pioneering biopharmaceutical company focused on the research and development of small interfering RNA (siRNA) innovative drugs, with an integrated drug development system from target discovery to clinical proof of concept [2] - The strategic acquisition is expected to accelerate the group's innovation and clinical advancement in chronic disease areas, particularly in weight loss metabolism, cardiovascular, and neurological diseases [2] - Hejia has developed a differentiated delivery platform with independent intellectual property rights, including the MVIP (Multi-Valent Import Platform), which is the world's first clinically validated liver-targeted delivery platform capable of providing long-lasting treatment with "one injection per year" [2]